Global Sildenafil Citrate Market Size, Forecast, and Trend Highlights Over 2025-2037
Sildenafil Citrate Market size was valued at USD 2.4 billion in 2024 and is projected to reach USD 4.4 billion by the end of 2037, rising at a CAGR of 6.3% during the forecast period, i.e., 2025 to 2037. In 2025, the industry size of sildenafil citrate is estimated at USD 2.6 billion.
The market is witnessing tremendous growth, shaped by its large patient pool affected by erectile dysfunction. For instance, a NIH 2023 report states that nearly 52.6 million men across all nations are diagnosed with erectile dysfunction, and a CDC report published in 2024 reported 14,500 to 21,000 cases of pulmonary arterial hypertension in a year. According to a clinical study by the WHO found that the U.S. alone accounts for more than 35% of ED-associated prescriptions, and similarly, developing nations such as India and China dominate with more than 58% of affordable sildenafil production. This has further encouraged investment in available efficient treatment procedures for such disorders.
The growth in the sildenafil citrate market is further influenced by global trade activities and research in the field. In this regard WTO in 2024 disclosed that USD 1.2 billion exports were carried out in 2023, which was led by India with USD 480 million, followed by Israel with USD 220 million. Besides, in 2023, NIH allocated USD 125 million for cardiovascular drug delivery systems, and the Horizon Europe program funded € 90 million for pulmonary hypertension therapies in 2024. Meanwhile, the CPI and PPI for sildenafil APIs enhanced by 4.1% and 2.3% attributed to the patent cliffs and affordability. Hence, these factors appreciably contribute to the market expansion.
Sildenafil Citrate Sector: Growth Drivers and Challenges
Growth Drivers
-
Increasing awareness of disease detection: There is a fast-rising prevalence of erectile dysfunction that increases diagnostic awareness, driving growth in the sildenafil citrate market. In this regard, CDC screening initiatives reported that there is a surge in PAH cases in 2023, with an increase of 40%, reflecting the improved diagnostic cases. Besides, USPSTF now highly recommends ED screening for diabetes in men, expanding the patient pool for phosphodiesterase-5 inhibitors. Hence, these factors, coupled with increasing awareness and accessibility to affordable therapeutics, are expected to propel market growth.
-
Patent expirations and affordable therapeutics: The demand for generics and patent expirations is another major driver for the sildenafil citrate market. In this regard, the U.S. FDA orange book reported that there have been 78 sildenafil approvals since 2020, reflecting the exceptional regulatory support. Besides, the lowered prices by 75% when compared to branded therapeutics are expanding business in emerging nations. Furthermore, the WHO report stated that its prequalification accelerated generic adoption in 14 developing countries. Therefore, this further drags the interest of global players to invest in effective therapeutics.
Strategic Manufacturer Initiatives Driving Sildenafil Citrate Market Growth
The sildenafil citrate market is gaining traction due to the strategic manufacturer initiatives opted for by the leading pharmaceutical firms. Key trends opted by the players include vertical integration, product innovation, and collaborations to capture maximum revenue growth. The U.S. FDA in 2023 reported its approval for Pfizer Inc.’s Viagra ODT formulation, which gained additional revenue of USD 325 million. Hence, these strategies are reshaping the global market significantly.
Revenue Opportunities for Sildenafil Citrate Manufacturers
|
Company |
Strategy |
Revenue Impact |
|
Pfizer Inc. |
ODT formulation launch |
+USD 325 million |
|
Teva Pharmaceuticals |
API backward integration |
20% cost reduction |
|
Aurobindo Pharma |
WHO-prequalified generics for Africa |
+ USD 96 million |
|
Viatris |
Sustained-release R&D (NIH-funded) |
+ USD 80 million |
Feasible Expansion Models Shaping the Sildenafil Citrate Market
Companies involved in the market are emphasizing different sorts of expansion models, such as partnerships, domestic production, and regulatory support from governing bodies. For instance, the National Institute of Health reported that in India, Aurobindo Pharma announced a partnership with the National Health Mission, which increased revenue by 15% from 2022 to 2024 through government tenders. Hence, these models are highly essential for market expansion, particularly in developing nations.
Feasibility Models for Sildenafil Citrate Market Expansion
|
Model |
Region |
Outcome |
|
PPP with the Govt. Healthcare |
India |
15% revenue growth |
|
FDA Fast-Track Approvals |
USA |
USD 225 million in new generic revenue |
|
WHO Prequalification |
Africa |
USD 96 million market capture |
Challenges
- Patent litigation risks: One of the most significant hurdles experienced by the sildenafil citrate market is the legal challenges that potentially delay the product’s market entry. In this context, the USPTO in 2024 reported that paragraph IV filings lead to an average legal cost, acting as a major market restraint. Besides, once patents expire or are invalidated, it results in high competitive pressures in the sector, making it restrictive for the manufacturer to opt for sildenafil citrate products.
Sildenafil Citrate Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.3% |
|
Base Year Market Size (2024) |
USD 2.4 billion |
|
Forecast Year Market Size (2037) |
USD 4.4 billion |
|
Regional Scope |
|
Sildenafil Citrate Segmentation
Application (Erectile Dysfunction Treatment, Pulmonary Arterial Hypertension)
Based on application, the erectile dysfunction treatment segment is expected to hold the highest share of 58.5% in the sildenafil citrate market by the end of 2037. The dominance of the segment is attributable to the increasing burden of erectile dysfunction among the geriatric population, mostly in regions such as North America and Europe. The WHO report states that by 2030, 1 out of 6 people worldwide will be over 60, amplifying demand for ED treatments. Besides the growing awareness, destigmatization of the disease, coupled with improved access to healthcare, is expected to augment the segment’s dominance. The global shift toward generic sildenafil citrate as an affordable alternative to branded Viagra also fuels market expansion.
Distribution channel (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies)
Based on distribution channel, the retail pharmacies segment is projected to account for a lucrative share of 48.2% in the sildenafil citrate market during the forecast period. The growth in the segment is primarily owing to the widespread availability of over-the-counter medications and in-person consultations. Besides, in emerging nations such as the UK and certain parts of Asia, sildenafil has been designated as a pharmacy medicine rather than a prescription-only drug, which enabled easier access through local pharmacies. Furthermore, as per a WHO report published in 2022, retail pharmacies are crucial in offering access to medications, particularly where healthcare access is limited. Hence, this is the evidence for a wider scope, thereby amplifying growth in the segment.
Our in-depth analysis of the sildenafil citrate market includes the following segments:
|
Application |
|
|
Type |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportSildenafil Citrate Industry - Regional Synopsis
North America Market Analysis
North America is a key player in the sildenafil citrate market, projected to register a significant share of 40.6% in 2037. The region benefits from a substantial consumer base, insurance coverage offered by public healthcare systems such as Medicare and Medicaid, and the bolster accessibility of over-the-counter drugs. In this regard, the Medicare expenditure for therapeutics associated with erectile dysfunctions increased by 20% from 2020 to 2024 which reaching USD 850 million, reflecting government support. Besides, the U.S. FDA approved generic sildenafil, which has significantly driven affordability, thereby readily blistering the region’s growth.
The Canada market is unfolding significant growth opportunities with a surge in OTC sales from 2019, as reported by Health Canada. Besides, the public health systems of Ontario are readily enhancing their expenditures for erectile dysfunction treatments, which rose by 20% from 2021 to 2024, serving more than 195,000 patients in the country. CIHA states that the generic version of sildenafil accounts for more than 60% of prescriptions due to its affordability in Canada. Additionally, in 2023 federal healthcare allocated a substantial 8.5%, which is USD 3.3 billion, for sexual health drugs, denoting a positive outlook for market expansion.
APAC Market Statistics
Asia Pacific’s sildenafil citrate market is witnessing the fastest growth with a considerable share of 22.5% by 2037, owing to the expansion of e-pharmacy, rising awareness of erectile dysfunction diagnosis, and affordability of generics. Besides, the business in the sector is fueled by the presence of a large consumer base, government healthcare expenditure, and domestic pharmaceutical firms. Countries such as India, China, Japan, and South Korea significantly contribute to the APAC market with their evolutionary prosperity.
India is a key leader in the market, comprising a share of 45.3% in the Asia Pacific region, fueled by factors such as affordable generics offering more than 75% of market penetration. Besides, the patient pool reached nearly 2.5 million as reported by the CDSCO. Governing bodies in the country are offering their support with funding initiatives, that is, the spending reached USD 1.9 billion, which is an increase of 20% over the last decade, expanding healthcare access. Local pharmaceutical manufacturing is on the rise, further driving business in the sector.
Companies Dominating the Sildenafil Citrate Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Cipla Ltd.
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
- Lupin Limited
- Dr. Reddy's Laboratories Ltd.
- Zydus Cadila
- Sandoz (Novartis)
- Bayer AG
- Eli Lilly and Company
- Alembic Pharmaceuticals Ltd.
- Amneal Pharmaceuticals LLC
- Apotex Inc.
- Hetero Drugs Ltd.
- Ajanta Pharma Ltd.
- Hikma Pharmaceuticals
- Centurion Laboratories
- Yabang Pharma
The sildenafil citrate market is experiencing a gain in traction due to the intensifying competition between the global firms. The key trend that shaped the global market landscape is the expiration of Viagra’s patent, which dragged the interest of leading pharmaceutical firms to develop effective formulations. The domestic players in emerging nations are prioritizing affordable therapeutic production and enhanced distribution hubs to enhance their ecosystem in the global market. Furthermore, collaborations, acquisitions to expand the product portfolio also significantly contribute to the market expansion.
Here's the list of some key players:
Recent Developments
- In March 2024, Johnson & Johnson MedTech announced a partnership with Nvidia to accelerate secure, real-time analysis of surgical data using artificial intelligence (AI) to enhance surgical decision-making, teamwork, and education in all linked operating rooms, potentially improving patient outcomes.
- In June 2023, CMP Pharma, Inc. launched Liqrev (Sildenafil) Oral Suspension, the first FDA-approved ready-made liquid formulation of sildenafil for patients with dysphagia (difficulty swallowing).
Author Credits: Radhika Pawar
- Report ID: 2582
- Published Date: Jun 02, 2025
- Report Format: PDF, PPT
